^
Association details:
| Biomarker: | TP53 overexpression + CD5 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma
Excerpt:
Of the 631 cases of CD5- DLBCL, only 111 cases (17.6%) showed p53 overexpression. In contrast, p53 was overexpressed in 30 (46.9%) of 64 CD5+ DLBCL... However, patients with p53 and CD5 co-overexpression had the worst PFS and OS (P < 0.001, PFS and OS, respectively)...
DOI:
https://doi.org/10.1182/blood-2019-127666
